middle.news
Vectus Converts VB4-P5 Compound into 9.9% Stake in XORTX
8:22am on Tuesday 14th of April, 2026 AEST
•
Healthcare
Read Story
Vectus Converts VB4-P5 Compound into 9.9% Stake in XORTX
8:22am on Tuesday 14th of April, 2026 AEST
Key Points
Sale of VB4-P5 renal fibrosis compound to XORTX finalised
Vectus receives 154,544 shares and 692,150 pre-funded warrants in XORTX
Shares represent 9.9% ownership in XORTX Therapeutics
Vectus retains license for non-renal fibrosis uses of VB4-P5 IP
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE